Haleon plc reports that it has issued an exhibit dated 11 August 2026 describing a cash tender offer for its outstanding 2027 3.375% Fixed Rate Notes. The filing identifies the company as a foreign private issuer and provides notice of this debt-related transaction to U.S. investors.
Haleon plc has launched a cash tender offer for its outstanding 2027 3.375% Fixed Rate Notes. The company states that this tender offer, together with a planned issue of new bonds, is in line with its previously stated capital allocation priorities and is expected to help proactively manage and optimise its debt portfolio.
The detailed terms of the tender offer are provided in a separate announcement available via the London Stock Exchange and on Haleon’s investor website, and have also been submitted to the UK Financial Conduct Authority’s National Storage Mechanism.
Haleon plc reports its share capital and voting structure as at 31 July 2026. The company has 8,820,906,422 ordinary shares of £0.01 each issued, of which 11,879,800 are held as treasury shares. This results in 8,809,026,622 ordinary shares with voting rights.
This voting-share figure is the denominator shareholders and others with notification obligations should use to determine whether they must notify their interest in Haleon under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon plc submitted an amended Form 6-K/A to update the reference to its latest shelf registration statement on Form F-3 filed on 29 July 2026. The amendment also confirms that the 30 July 2026 half year results are incorporated by reference into the Form F-3 (No. 333-297789) and the Form S-8 (No. 333-267647).
Haleon plc announced that its 2026 half year results statement for the year ending 31 December 2026 is now available on its investor website and through the UK Financial Conduct Authority’s National Storage Mechanism.
The Board declared an H1 2026 interim dividend of 2.4 pence per ordinary share, a 9% increase on the 2025 interim dividend and in line with the policy of paying about one third of the prior full-year dividend at the interim stage. The dividend is expected to be paid on 17 September 2026 to holders of ordinary shares and ADS on the register as of 14 August 2026, with ex-dividend dates of 13 August 2026 for ordinary shares and 14 August 2026 for ADS. A Dividend Reinvestment Programme is available with an election deadline of 28 August 2026. Management will provide a recorded results presentation and a Q&A session for analysts and shareholders on 30 July 2026.
Haleon plc reported H1 2026 revenue of £5,602m, up 2.2% on a reported basis and 2.6% organically. Reported gross margin rose to 65.9%, while adjusted gross margin reached 66.5%. Adjusted operating profit increased to £1,364m, with margin expanding to 24.3%, although reported operating profit declined 2.6% to £1,172m due mainly to restructuring costs linked to an operating model change.
Reported diluted EPS fell 4.5% to 8.5p, but adjusted diluted EPS rose 12.0% to 10.3p, helped by higher adjusted profit and a smaller share count. Net cash from operating activities was £1,044m and free cash flow £769m. Net debt stood at £7.5bn (2.5x net debt/adjusted EBITDA) after repaying an €850m bond, and £457m of a £500m 2026 share buyback had been completed. An interim dividend of 2.4p per share, 9% above 2025, was declared.
Operationally, 73% of the business gained or maintained market share, with strong growth in Oral Health and Pain Relief partly offset by a decline in Respiratory Health following a weak cold and flu season. Guidance for 2026 is unchanged, with expected organic revenue growth of 3–5% and high single-digit adjusted operating profit growth at constant currency, supported by ongoing productivity programmes and a medium-term goal of 50–80bps annual adjusted gross margin expansion.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of common stock of Haleon plc. BlackRock reports beneficial ownership of 745,718,619 shares of Haleon common stock, representing 8.5% of the class.
BlackRock has sole voting power over 691,385,758 shares and sole dispositive power over 745,718,619 shares, with no shared voting or dispositive power reported. Various underlying clients or other persons have rights to dividends or sale proceeds from these shares, but no such person is reported to hold more than five percent of Haleon’s outstanding common shares.
Haleon plc reported that Chief Financial Officer Dawn Allen received a vesting of performance-based share awards under the Haleon Performance Share Plan. On 30 June 2026, she acquired 283,193.151771 ordinary shares at nil cost, reflecting achievement of performance conditions through 31 December 2025 and continued employment requirements.
As part of the same event, 133,300.732432 shares were automatically sold on the London Stock Exchange at £3.523867 per share to meet tax liabilities. The remaining shares are subject to Haleon’s shareholding requirements, as well as malus and clawback provisions designed to align executive rewards with long-term performance.
Haleon plc reports its share capital and voting rights position. As at 30 June 2026, the company has issued 8,820,906,422 ordinary shares of £0.01 each, of which 12,006,714 are held as treasury shares. This leaves 8,808,899,708 ordinary shares with voting rights. Shareholders and others with notification obligations are instructed to use this voting-rights figure as the denominator when assessing whether they must notify their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reports it has purchased 6,992,435 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The purchases were made on 22 and 23 June 2026 across the London Stock Exchange, Cboe UK venues and Aquis at volume weighted average prices around 332–334 pence per share.
After settlement, Haleon’s registered share capital is 8,820,906,422 ordinary shares, including 12,006,714 treasury shares. The number of ordinary shares with voting rights is now 8,808,899,708, which shareholders can use when assessing disclosure thresholds under UK transparency rules.